The Alzheimer's Association announced PROTECT-Cog on July 13, 2026 at its International Conference in London, committing $100 million to test whether a metabolism-targeting drug added to a structured lifestyle program cuts the risk of cognitive decline further than lifestyle change alone. The study population is older adults at increased risk of cognitive decline — not people already living with Alzheimer's dementia, who are outside the trial's scope. That distinction matters for anyone reading this because of their own memory concerns. PROTECT-Cog is a prevention trial, enrollment was still about a year away at the announcement, and the specific drug had not yet been chosen — so it offers no treatment today, only a direction the field is taking.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What PROTECT-Cog is actually testing
- Who is being studied, and who is not
- How the study is designed
- What a reader can act on now
- The other $100 million you may have read about
- Frequently Asked Questions
What PROTECT-Cog is actually testing
PROTECT-Cog stands for "Prevention of Risk fOr cogniTive dEcline through Combined Therapy." According to the Alzheimer's Association's announcement, the trial pairs a multidomain lifestyle program — exercise, diet, cognitive and social activity, cardiovascular monitoring — with a drug targeting metabolism, expected to be a GLP-1 receptor agonist. GLP-1 drugs are the class used for type 2 diabetes and weight management, including semaglutide. The question is additive, not either-or.
Lifestyle change already has evidence behind it; PROTECT-Cog asks whether treating the underlying biology on top of that produces a further reduction in risk. Maria C. Carrillo, the Association's chief science officer, is principal investigator and has framed the study as addressing lifestyle and biology together, building directly on the U.S. POINTER results.
Who is being studied, and who is not
The enrolled population is older adults at increased risk of cognitive decline. As Medscape reported from the launch, people already diagnosed with Alzheimer's dementia are not the target group, and PROTECT-Cog does not require biomarker-confirmed Alzheimer's disease — a notable contrast with the EVOKE and EVOKE+ semaglutide trials, which did. That means the trial is open, in principle, to people whose concern is risk rather than diagnosis: someone with a family history, poor cardiometabolic health, and no cognitive impairment on testing.
It is closed to people whose memory loss has already been diagnosed as dementia. Much of the "who is not" remains undecided rather than announced. At the launch, no enrollment target, no age floor, and no list of participating countries had been published. Full eligibility criteria are to be posted on the Association's trial finder once set.
How the study is designed
Participants are randomized between two versions of the same lifestyle program. One is intensively coached and structured; the other is a "structured-lite" arm carrying the same core content with fewer touchpoints, as described in EMJ's conference coverage. A subset of participants additionally receives the metabolic drug. Follow-up runs three years, with comprehensive cognitive and health evaluations every six months.
Tracked outcomes go beyond test scores: onset of mild cognitive impairment, frailty, and quality of life are all measured, according to NeurologyLive's report on the launch. The predecessor it builds on gives a reasonable picture of who prevention trials recruit. U.S. POINTER enrolled 2,111 cognitively unimpaired adults aged 60–79 who were sedentary, had suboptimal diet and cardiometabolic health, and had a family history of memory impairment. Mean age was 68.2, and 30.8% came from ethnoracial minority groups.
What a reader can act on now
No PROTECT-Cog results exist, and none are expected until roughly three years after enrollment opens — so sometime past 2030 on the timeline announced. The actionable evidence today is still U.S.
POINTER's: both structured and self-guided lifestyle programs improved cognition over two years, with the structured version performing better. Practical steps that follow from that finding, not from PROTECT-Cog:.
- Treat the cardiometabolic basics as brain care — blood pressure, blood sugar, and cholesterol were part of what POINTER's program addressed.
- Add structure where you can. Scheduled, coached activity beat self-directed effort in POINTER, which argues for a class, a group, or a clinician-set plan over good intentions.
- Raise GLP-1 drugs with your own physician as a metabolic question, not a memory one. Their effect on cognitive decline is exactly what PROTECT-Cog has yet to measure.
- Check the Alzheimer's Association trial finder if you want to enroll later; criteria will be published there.
The other $100 million you may have read about
Two separate $100 million figures appeared in 2026 coverage, and conflating them changes what the number means. One is the Association's commitment to this trial.
The other is a $100 million increase Congress approved for federal Alzheimer's and dementia research — appropriations spread across the federal research portfolio, not money going into PROTECT-Cog. If you see the figure cited without a named recipient, check which one is meant. The trial money funds one study; the appropriation funds many.
Frequently Asked Questions
Can I join PROTECT-Cog if I already have a dementia diagnosis?
No. The trial targets older adults at increased risk of cognitive decline, and people already diagnosed with Alzheimer's dementia are not the study population.
Do I need a brain scan or blood biomarker test to qualify?
Not for this trial. Unlike the EVOKE and EVOKE+ semaglutide studies, PROTECT-Cog does not require biomarker-confirmed Alzheimer's disease.
Which drug will participants receive?
It had not been selected as of the July 2026 announcement. The Association said it expects a GLP-1 receptor agonist.
When will results be available?
Enrollment was expected to begin roughly a year after the announcement, and participants are followed for three years, so findings are several years out.
You Might Also Like
- Food Access and Brain Health Research Priorities in 2026: Who Was Studied and Who Was Not for Spouses and Partners
- Implementation-Ready Dementia Interventions in the 2026 NIA Report: A Source-Checked Research Briefing for Adults With Memory Concerns
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: A Source-Checked Briefing for People With Mild Cognitive Impairment
